Skip to main content

Mobidiag C. difficile Test Receives CE Mark

NEW YORK (GenomeWeb) — Finland's Mobidiag announced today that its qualitative qPCR-based Clostridium difficile infection (CDI) test has received CE-IVD marking and is now available throughout Europe.

Called Amplidiag C. difficile+27, the test is able to detect CDI in stool samples by identifying the toxin B gene (tcdB), as well as differentiate the hypervirulence-associated 027 ribotype, in a single reaction.

In a study evaluating the test in 309 prospective and 35 spiked samples against toxigenic stool culture findings and independent molecular methods, it showed 100 percent specificity for both tcdB and the 027 ribotype, and sensitivities of 97.8 percent and 94.4 percent, respectively.

"CDI is a major cause of mortality and increased healthcare costs globally," Mobidiag CEO Tuomas Tenkanen said in a statement. "Early identification is important for guiding patient management and infection control measures … [as well as] lowering the overall healthcare costs of CDI."

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.